Integrated Diagnostics Holdings (FRA:8I8) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8I8 Integrated Diagnostics Holdings PLC FRA:8I8
58 GF Score
Price €0.43
GF Value €0.47
! 7 Warning Signs
View Full Analysis

What is Integrated Diagnostics Holdings FFO?

FFO (Funds from operations) only applies to REITs.

FRA:8I8
58GF Score
Integrated Diagnostics Holdings PLC FRA:8I8
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Integrated Diagnostics Holdings (FRA:8I8) Overvalued in 2026?

Based on GuruFocus' analysis, Integrated Diagnostics Holdings stock appears to be undervalued. The current stock price of €0.43 is trading 9.4% below its estimated GF Value™ of €0.47.

Key valuation signals for FRA:8I8:

  • FFO:
  • GF Value™: €0.47 vs. price of €0.43 (9.4% below fair value)
  • GF Score™: 58/100 with 7 warning signs

No single metric tells the full story. See the FRA:8I8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Integrated Diagnostics Holdings Business Description

Other Exchanges IDGXF:USAIDHCl:UKIDHC:UK
Address 12 Castle Street, St Helier, JEY, JE2 3RT
Integrated Diagnostics Holdings PLC is active in the healthcare sector. It is a fully integrated diagnostics service provider, operating through brands such as Al Borg and Al Mokhtabar in Egypt, as well as Biolab in Jordan and Ultralab and Al Mokhtabar Sudan in Sudan, Echo-Lab in Nigeria, and Biolab KSA in Saudi Arabia. The company specializes in diagnostic tests, ranging from basic tests, such as glucose testing for diabetes, to molecular tests for hepatitis and specialized DNA tests. The company operates in two segments: the Contract Segment, which generates key revenue, and the Walk-in Segment. It derives a majority of its revenue from services offered in Egypt.
58GF Score

Get the complete analysis for FRA:8I8

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.43
Price
€0.47
GF Value